

Stefano Caruso

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5420038/stefano-caruso-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

57
papers

1,473
citations

24
h-index

37
g-index

68
ext. papers

2,180
ext. citations

7.6
avg, IF

4.55
L-index

#	Paper	IF	Citations
57	Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.. <i>Journal of Hepatology</i> , 2022 ,	13.4	6
56	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.. <i>Lancet Oncology, The</i> , 2022 , 23, 161-171	21.7	1
55	Deleting the E-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth.. <i>Journal of Hepatology</i> , 2022 ,	13.4	2
54	Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.. <i>Lancet Oncology, The</i> , 2022 ,	21.7	6
53	TGFβ-induced FOXS1 controls epithelial-mesenchymal transition and predicts a poor prognosis in liver cancer. <i>Hepatology Communications</i> , 2021 ,	6	1
52	Immune profiling of combined hepatocellular-cholangiocarcinoma reveals distinct subtypes and activation of gene signatures predictive of response to immunotherapy. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
51	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. <i>Journal of Hepatology</i> , 2021 ,	13.4	3
50	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021 , 13,	6.6	4
49	AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, G543-G556	5.1	4
48	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. <i>Cancer Discovery</i> , 2021 , 11, 2524-2543	24.4	4
47	Expression of NKG2D ligands is downregulated by E-catenin signalling and associates with HCC aggressiveness. <i>Journal of Hepatology</i> , 2021 , 74, 1386-1397	13.4	17
46	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. <i>Genome Medicine</i> , 2021 , 13, 113	14.4	7
45	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	6
44	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021 , 81, 4910-4925	10.1	6
43	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. <i>Hepatology</i> , 2021 , 73 Suppl 1, 14-26	11.2	34
42	The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. <i>Oncogene</i> , 2021 , 40, 127-139	9.2	11
41	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021 , 74, 1155-1166	13.4	11

40	The lncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD. <i>Cancers</i> , 2021 , 13,	6.6	3
39	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2021 ,	19.2	29
38	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. <i>Hepatology</i> , 2021 , 74, 816-834	11.2	7
37	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021 , 60, 1499-1506	3.2	6
36	Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020 , 15, e113-e116	8.9	2
35	Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. <i>Molecular Oncology</i> , 2020 , 14, 1207-1223	7.9	38
34	Recurrent chromosomal rearrangements of , and activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020 , 69, 1667-1676	19.2	8
33	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020 , 72, 924-936	13.4	18
32	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ER and HNF1	6.6	2
31	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. <i>PLoS ONE</i> , 2020 , 15, e0238809	3.7	3
30	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020 , 71, 164-182	11.2	62
29	Polyploidy spectrum: a new marker in HCC classification. <i>Gut</i> , 2020 , 69, 355-364	19.2	34
28	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020 , 69, 737-747	19.2	36
27	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e981-e994	3.3	22
26	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019 , 71, 323-332	13.4	6
25	germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. <i>Oncolmmunology</i> , 2019 , 8, e1583547	7.2	16
24	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 160-178	11.2	20
23	Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019 , 69, 587-603	11.2	56

22	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 5859-5865	12.9	26
21	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e909-e912	3.3	1
20	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019 , 157, 760-776	13.3	77
19	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018 , 68, 964-976	11.2	25
18	Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. <i>Cancer Cell</i> , 2018 , 33, 1061-1077.e6	24.3	88
17	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. <i>Gastroenterology</i> , 2018 , 155, 1951-1966.e26	13.3	49
16	Palmitoylation is a post-translational modification of Alix regulating the membrane organization of exosome-like small extracellular vesicles. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018 , 1862, 2879-2887	4	24
15	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017 , 66, 734-742	13.4	25
14	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017 , 152, 880-894.e6	13.3	198
13	Potential Role of ANGPTL4 in the Cross Talk between Metabolism and Cancer through PPAR Signaling Pathway. <i>PPAR Research</i> , 2017 , 2017, 8187235	4.3	86
12	HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 97, 312-21	7	28
11	Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. <i>Oncotarget</i> , 2016 , 7, 47821-47830	3.3	28
10	Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. <i>Current Pharmaceutical Biotechnology</i> , 2014 , 15, 475-85	2.6	47
9	Effects of PPAR α agonists on the expression of leptin and vascular endothelial growth factor in breast cancer cells. <i>Journal of Cellular Physiology</i> , 2013 , 228, 1368-74	7	26
8	HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. <i>Breast Cancer Research and Treatment</i> , 2013 , 140, 505-17	4.4	25
7	Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense?. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 1249-61	6.4	35
6	Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. <i>BioMed Research International</i> , 2013 , 2013, 746858	3	24
5	High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. <i>Journal of Cellular and Molecular Medicine</i> , 2013 , 17, 1025-37	5.6	62

4	MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2013 , 04,	1	2
3	Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 2186-95	5.6	21
2	MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness?. <i>Oncogenesis</i> , 2012 , 1, e32	6.6	37
1	LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways. <i>Liver Cancer</i> , 1-15	9.1	0